Literature DB >> 9815215

Human submandibular saliva inhibits human immunodeficiency virus type 1 infection by displacing envelope glycoprotein gp120 from the virus.

T Nagashunmugam1, D Malamud, C Davis, W R Abrams, H M Friedman.   

Abstract

Human submandibular saliva reduces human immunodeficiency virus type 1 (HIV-1) infection in vitro. To define the mechanism of inhibition, virus was incubated with saliva or medium, velocity sucrose gradient centrifugation was performed, and fractions were analyzed for p24 and gp120. The results show that after incubation with saliva, the envelope glycoprotein was displaced from both a laboratory-adapted and a low-passage clinical HIV-1 isolate. To identify the salivary protein(s) responsible, submandibular saliva was fractionated by anion- exchange chromatography. Protein fractions containing anti-HIV activity were assayed for their ability to strip gp120 from virus. The partially purified active fractions contained two high-molecular-weight sialyated glycoproteins identified as salivary agglutinin and mucin, as well as several lower-molecular-weight proteins. It thus appears that specific salivary proteins interact with HIV-1 to strip gp120 from the virus with a resultant decrease in infectivity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9815215     DOI: 10.1086/314511

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  23 in total

Review 1.  Antiviral activities in human saliva.

Authors:  D Malamud; W R Abrams; C A Barber; D Weissman; M Rehtanz; E Golub
Journal:  Adv Dent Res       Date:  2011-04

2.  Characterization of SIV in the oral cavity and in vitro inhibition of SIV by rhesus macaque saliva.

Authors:  Jessica S Thomas; Nedra Lacour; Pamela A Kozlowski; Steve Nelson; Gregory J Bagby; Angela M Amedee
Journal:  AIDS Res Hum Retroviruses       Date:  2010-08       Impact factor: 2.205

3.  Comparison of human immunodeficiency virus type 1-specific inhibitory activities in saliva and other human mucosal fluids.

Authors:  Shamim H Kazmi; Julian R Naglik; Simon P Sweet; Robert W Evans; Siobhan O'Shea; Jangu E Banatvala; Stephen J Challacombe
Journal:  Clin Vaccine Immunol       Date:  2006-08-23

Review 4.  Current status of mucins in the diagnosis and therapy of cancer.

Authors:  Satyanarayana Rachagani; Maria P Torres; Nicolas Moniaux; Surinder K Batra
Journal:  Biofactors       Date:  2009 Nov-Dec       Impact factor: 6.113

Review 5.  The mouth: a gateway or a trap for HIV?

Authors:  Daniel Malamud; Sharon M Wahl
Journal:  AIDS       Date:  2010-01-02       Impact factor: 4.177

Review 6.  The oral mucosa immune environment and oral transmission of HIV/SIV.

Authors:  Lianna F Wood; Ann Chahroudi; Hui-Ling Chen; Heather B Jaspan; Donald L Sodora
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

7.  An electrochemiluminescence assay for gp340 (DMBT1).

Authors:  Cheryl Barber; Drew Weissman; Kurt Barnhart; Minal Dalvi; William R Abrams; Daniel Malamud
Journal:  Anal Biochem       Date:  2013-05-30       Impact factor: 3.365

8.  HIV envelope binding by macrophage-expressed gp340 promotes HIV-1 infection.

Authors:  Georgetta Cannon; Yanjie Yi; Houping Ni; Earl Stoddard; David A Scales; Donald I Van Ryk; Irwin Chaiken; Daniel Malamud; Drew Weissman
Journal:  J Immunol       Date:  2008-08-01       Impact factor: 5.422

9.  gp340 promotes transcytosis of human immunodeficiency virus type 1 in genital tract-derived cell lines and primary endocervical tissue.

Authors:  Earl Stoddard; Houping Ni; Georgetta Cannon; Chunhui Zhou; Neville Kallenbach; Daniel Malamud; Drew Weissman
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

10.  A variant form of the human deleted in malignant brain tumor 1 (DMBT1) gene shows increased expression in inflammatory bowel diseases and interacts with dimeric trefoil factor 3 (TFF3).

Authors:  Jens Madsen; Grith Lykke Sorensen; Ole Nielsen; Ida Tornøe; Lars Thim; Claus Fenger; Jan Mollenhauer; Uffe Holmskov
Journal:  PLoS One       Date:  2013-05-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.